HC Wainwright Issues Negative Forecast for Humacyte Earnings

Key Points

• HC Wainwright has lowered its Q3 2025 EPS estimate for Humacyte to ($0.18), down from a prior estimate of ($0.13), while maintaining a "Buy" rating with a $3.00 target price.
• Humacyte reported a Q2 2025 EPS of ($0.24), missing the consensus estimate of ($0.15), with revenue significantly lower than expected at $0.30 million versus a $0.94 million estimate.
• Investment analysts have varied outlooks on Humacyte, with ratings ranging from "sell" to "strong buy," contributing to a current average rating of "Moderate Buy" and a consensus price target of $10.64.

Humacyte, Inc. (NASDAQ:HUMA - Free Report) - Investment analysts at HC Wainwright decreased their Q3 2025 earnings per share estimates for shares of Humacyte in a research note issued to investors on Tuesday, August 12th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.18) per share for the quarter, down from their previous estimate of ($0.13). HC Wainwright has a "Buy" rating and a $3.00 price target on the stock. The consensus estimate for Humacyte's current full-year earnings is ($1.27) per share. HC Wainwright also issued estimates for Humacyte's Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.75) EPS, FY2026 earnings at ($0.67) EPS, FY2027 earnings at ($0.43) EPS and FY2028 earnings at $0.03 EPS.

Several other brokerages also recently weighed in on HUMA. Wall Street Zen downgraded Humacyte from a "hold" rating to a "sell" rating in a research note on Sunday. TD Cowen lowered their target price on Humacyte from $5.00 to $3.50 and set a "buy" rating for the company in a research note on Tuesday, August 12th. Benchmark lowered their target price on Humacyte from $17.00 to $14.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Finally, D. Boral Capital restated a "buy" rating and set a $25.00 target price on shares of Humacyte in a research note on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $10.64.

Humacyte Stock Down 10.8%

NASDAQ HUMA traded down $0.1950 during trading hours on Thursday, hitting $1.6050. The company had a trading volume of 5,825,525 shares, compared to its average volume of 4,013,612. Humacyte has a fifty-two week low of $1.15 and a fifty-two week high of $7.48. The company has a market capitalization of $248.97 million, a price-to-earnings ratio of -3.57 and a beta of 1.90. The company has a debt-to-equity ratio of 2.97, a current ratio of 2.45 and a quick ratio of 1.93. The firm's 50 day moving average is $2.30 and its 200 day moving average is $2.41.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.09). The company had revenue of $0.30 million during the quarter, compared to analysts' expectations of $0.94 million.

Hedge Funds Weigh In On Humacyte

Large investors have recently bought and sold shares of the business. Columbia Advisory Partners LLC bought a new position in Humacyte in the first quarter worth about $27,000. Lazari Capital Management Inc. bought a new stake in Humacyte during the second quarter worth approximately $27,000. Prudential Financial Inc. bought a new stake in Humacyte during the second quarter worth approximately $28,000. Financial Advisors Network Inc. bought a new stake in Humacyte during the second quarter worth approximately $28,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Humacyte during the 2nd quarter valued at $30,000. Institutional investors own 44.71% of the company's stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.